chlormethine hydrochloride


( Last Updated : July 22, 2021)
Generic Name:
chlormethine hydrochloride
Project Status:
Active
Therapeutic Area:
T-cell lymphoma
Manufacturer:
Recordati Rare Diseases Canada Inc.
Brand Name:
Ledaga
Project Line:
Reimbursement Review
Project Number:
PC0242-000

Details


Manufacturer Requested Reimbursement Criteria1:
For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 23, 2020
Call for patient/clinician input closedJanuary 22, 2021
Clarification:

- Patient input submission received from Lymphoma Canada, Canadian Skin Patient Alliance and Cutaneous Lymphoma Foundation

Submission receivedDecember 21, 2020
Submission acceptedJanuary 12, 2021
Review initiatedJanuary 13, 2021
Draft CADTH review report(s) provided to sponsor for commentApril 16, 2021
Deadline for sponsors commentsApril 27, 2021
CADTH responses on draft review report(s) provided to sponsorMay 31, 2021
Expert committee meeting (initial)June 10, 2021
Draft recommendation issued to sponsorJune 24, 2021
Draft recommendation posted for stakeholder feedbackJuly 08, 2021
End of feedback periodJuly 22, 2021
Clarification:

- Reconsideration: major revisions requested by sponsor